<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="publisher-id">OXIMED</journal-id><journal-title-group><journal-title>Oxidative Medicine and Cellular Longevity</journal-title></journal-title-group><issn pub-type="ppub">1942-0900</issn><issn pub-type="epub">1942-0994</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21150340</article-id><article-id pub-id-type="pmc">3154038</article-id><article-id pub-id-type="doi">10.4161/oxim.3.5.13199</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Efficacy of Combination Therapy with Telmisartan Plus Amlodipine in Patients with Poorly Controlled Hypertension</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bekki</surname><given-names>Hisatoshi</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1</sup>
					</xref></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Kiichiro</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1</sup>
					</xref></contrib><contrib contrib-type="author"><name><surname>Sone</surname><given-names>Masayoshi</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1</sup>
					</xref></contrib><contrib contrib-type="author"><name><surname>Homma</surname><given-names>Tomoki</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1</sup>
					</xref></contrib><contrib contrib-type="author"><name><surname>Nakata</surname><given-names>Masashi</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1</sup>
					</xref></contrib><contrib contrib-type="author"><name><surname>Nohara</surname><given-names>Masatoshi</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1</sup>
					</xref></contrib><contrib contrib-type="author"><name><surname>Fukami</surname><given-names>Kei</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1, 2</sup>
					</xref><xref ref-type="aff" rid="I2">
					</xref></contrib><contrib contrib-type="author"><name><surname>Okuda</surname><given-names>Seiya</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1, 2</sup>
					</xref><xref ref-type="aff" rid="I2">
					</xref></contrib><contrib contrib-type="author"><name><surname>Yamagish</surname><given-names>Sho-ichi</given-names></name><xref ref-type="aff" rid="I1">
						<sup>1, 3</sup>
					</xref><xref ref-type="aff" rid="I3">
					</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>ABC Trial Group,  Kurume, Japan</aff><aff id="I2"><sup>2</sup>Department of Medicine,  Division of Nephrology,  Kurume University School of Medicine,  Kurume, Japan</aff><aff id="I3"><sup>3</sup>Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications,  Kurume University School of Medicine,  Kurume, Japan</aff><author-notes><corresp id="cor1">*Sho-ichi Yamagish: <email>shoichi@med.kurume-u.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2010</year></pub-date><volume>3</volume><issue>5</issue><fpage>342</fpage><lpage>346</lpage><history><date date-type="received"><day>26</day><month>7</month><year>2010</year></date><date date-type="rev-recd"><day>29</day><month>7</month><year>2010</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2010 Hindawi Publishing Corporation.
</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>There is accumulating evidence that blood pressure (BP) control significantly reduces the risk of future cardiovascular events in patients with essential hypertension. However, strict BP control is often difficult to maintain, and half of hypertensive patients fail to attain BP goals on single-drug therapy. Therefore, current guidelines recommend combinations of drugs that have complimentary mode of actions for treatment of patients with moderate hypertension. In this study, we examined in hypertensive patients uncontrolled by the combination treatment with 5 mg amlodipine plus 80 mg valsartan or 8 mg candesartan whether additional BP lowering could be achieved by switching to 5 mg amlodipine plus 40 mg telmisartan. Forty-seven patients with essential hypertension who failed to achieve a target BP level by the treatment of 5 mg amlodipine plus 80 mg valsartan or 8 mg candesartan for at least 2 months were enrolled. Replacement of valsartan or candesartan by telmisartan showed a significant reduction in both mean clinic systolic and diastolic BP at 4, 8 and 12 weeks; BP level decreased from 143.7/82.3 mmHg at baseline to 135.4/77.5 mmHg at 12 weeks. Furthermore, in 8 patients of valsartan group, switching to telmisartan significantly reduced central BP by 11.8 mmHg. Our present study suggests that combination therapy with telmisartan plus amlodipine may be more beneficial than valsartan or candesartan plus amolodipine treatment for controlling brachial and central BP, which could lead to more favorable cardiovascular outcomes with this drug combinations.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>There is a growing body of evidence that blood pressure (BP) level is one of the major determinants of cardiovascular morbidity and mortality in individuals [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. A recent analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) revealed that any commonly used BP-lowering regimen reduced the risk of total major cardiovascular events, and larger lowering in BP level produced larger reductions in the risk [<xref ref-type="bibr" rid="B3">3</xref>]. These observations suggest that most of the differences among treatment regimens in their effects on cardiovascular outcomes could be explained by the differences in achieved BP level. However, it may also be true that some treatment regimen is superior or inferior to others with regard  to the risk reduction of cardio-vascular events [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>]. Indeed, in Avoiding Cardiovascular Events through Combination  Therapy in  Patients  with Living with Systolic Hypertension  (ACCOMPLISH) trial, combination of the inhibitor of rennin-angiotensin system (RAS) with amlodipine, one of the most widely used dihydropyridine calcium channel blocker (CCB), demonstrated a significant risk reduction incardiovascular events in patients with hypertension compared to the R AS inhibitor-hydrochlorothiazide combination [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Angiotensin II (Ang II) is a physiologically active major sub- stance of the R AS; it not only acts as a vasopressor by inducing vasoconstriction, but also elicits water and sodium absorption in the proximal renal tubule by stimulating secretion of aldosterone [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. Furthermore, Ang II exerts various biological effects in blood vessel, kidney and heart via the interaction with type 1 receptor [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. Therefore, inhibition of the RAS by angiotensin-converting enzyme inhibitors (ACEIs) and/or Ang II type 1 receptor blockers (ARBs) may be a therapeutic target for the organ protection in patients with hypertension [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>ARBs have less adverse reactions; they are unlikely to cause dry cough and angioedema associated with ACEIs [<xref ref-type="bibr" rid="B9">9</xref>].  Since risk of cough from ACEIs is relatively high in East Asian compared with white patients, [<xref ref-type="bibr" rid="B10">10</xref>] ARBs are now a more popular R AS inhibitor in Japan. Although CCBs and ARBs are one of the recommended combinations in order to achieve target BP level, [<xref ref-type="bibr" rid="B11">11</xref>] optimal combination regimen is not well established. Valsartan, candesartan and telmisartan are effective and well-tolerated ARBs, and their usual dosages are 80 mg, 8 mg and 40 mg once daily, respectively in Japan [<xref ref-type="bibr" rid="B12">12</xref>]. Therefore, we examined in hypertensive patients whose BP level was uncontrolled by combination treatment with 5 mg amlodipine plus 80 mg valsartan or 8 mg candesartan for at least 2 months whether additional BP lowering could be achieved by switching to 5 mg amolodipine plus 40 mg telmisartan. We also investigated whether combination therapy with telmisartan and amlodipine was more effective in reducing central aortic pressures compared with valsartan or candesartan plus amlodipine treatment.</p></sec><sec sec-type="section" id="sec2"><title>2. Results</title><p>Demographical data of the subjects are presented in <xref ref-type="table" rid="tab1">Table 1</xref>. As shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, replacement of valsartan or candesartan bytelmisartan in amlodipine-treated hypertensive patients showed a significant reduction in both mean clinic systolic BP (SBP) and diastolic BP (DBP) at 4, 8 and 12 weeks; BP level decreased from 143.7/82.3 mmHg at baseline to 135.4/77.5 mmHg at 12 weeks after the telmisartan treatment. When valsartan and candesartan group was separately analyzed, switching from valsartan to telmisartan had more beneficial BP-lowering effects (Figs. 2 and 3); replacement of valsartan by telmisartan reduced mean SBP and DBP by 7.1 and 6.5 mmHg at 4 weeks, 6.9 and 5.0 mmHg at 8 weeks, 10.5 and 7. mmHg at 12 weeks, respectively. Furthermore, although central BP (cBP) and augmentation index (AI) were evaluated in only 8 patients of valsartan group, switching to telmisartan significantly reduced cBP by 11.8 mmHg (<xref ref-type="table" rid="tab2">Table 2</xref>). There were no significant differences among low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), fasting plasma glucose (FPG), glycosyalted hemoglobin (HbA1c), insulin, homeostasis model assessment of insulin resistance (HOMA-IR) index, creatinine (Cr), estimated glomerular filtration rate (eGFR) values and AI before and after the treatment of telmisartan (Tables <xref ref-type="table" rid="tab1">1</xref> and <xref ref-type="table" rid="tab2">2</xref>).</p></sec><sec sec-type="section" id="sec3"><title>3. Discussion</title><p>Hypertension is one of the major risk factors of cardiovascular disease, and to control BP level appropriately is a therapeutic target for preventing future cardiovascular events in individuals [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. However, strict BP control is often difficult to maintain, and BP level is not adequately controlled in more than 50% of hypertensive patients on single-drug  therapy [<xref ref-type="bibr" rid="B15">15</xref>]. Therefore, current guidelines recommend combinations of drugs with different mode of actions for treatment of patients with moderate hypertension [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B16">16</xref>]. There are several papers to show that combination therapy with ARBs and amlodipine, one of the most popular CCBs is effective for BP control compared with high-dose monotherapy, although what types of ARBs in combination with amlodipine are more effective for achieving appropriate BP control is not well established [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>].</p><p>In this study, we demonstrated for the first time that in hypertensive patients uncontrolled by the combination treatment with 5 mg amlodipine plus 80 mg valsartan or 8 mg candesartan, additional BP lowering was achieved by switching to 5 mg amlodipine plus 40 mg telmisartan. BP level was significantly decreased at 4 weeks after the telmisartan treatment and remained low during the study periods. Furthermore, replacement of valsartan by telmisartan was found to significantly reduce cBP in our subjects as well. There are accumulating evidence that cBP is closely asso- ciated with coronary risk factors and future cardiovascular events in patients with hypertension [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>]. Therefore, our present findings suggest that combination therapy with telmisartan plus amlodipine may be more beneficial than valsartan or candesartan plus amolodipine treatment for controlling brachial and cBP, which could lead to more favorable cardiovascular outcomes with this drug combinations.</p><p>We have previously found that telmisartan has the strongest binding affinity to Ang II type 1 receptor among various ARBs, including valsartan  and  candesartan [<xref ref-type="bibr" rid="B21">21</xref>]. Further, telmisartan has a half-life of about 24 hours, which is longer than that of valsartan and candesartan (about 9 hours) [<xref ref-type="bibr" rid="B7">7</xref>]. Among the ARBs, telmisartan is the most lipophilic compound as well [<xref ref-type="bibr" rid="B22">22</xref>]. Therefore, due to its strongest Ang II type 1 receptor antagonistic ability, longest half-life and  lipophilicity, switching  to  telmisartan may have long-lasting BP lowering effects in our uncontrolled hypertensive  patients who  were treated with 5 mg amlodipine plus 80 mg valsartan or 8 mg  candesartan. In support of this, it has been reported in clinical studies that telmisartan is significantly superior to valsartan in anti- hypertensive effect during the daytime and early morning, [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>] and  that  it  produces  a  sustained antihypertensive effect equal to or  greater than amlodipine, a long-acting CCB [<xref ref-type="bibr" rid="B25">25</xref>]. Further, meta- analysis revealed that BP lowering effect of 40 mg telmisartan was stronger than that of 80 mg valsartan or 8 mg candesartan [<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec sec-type="section" id="sec4"><title>4. Research Design and Methods</title><sec sec-type="subsection" id="sec4.1"><title>
						Subjects
					</title><p>This was a prospective, open-label, 12-week study. Fortynine patients with essential hypertension not achieving a target clinic or home BP level were recruited from multiple centers in Japan [<xref ref-type="bibr" rid="B27">27</xref>]. All patients were taking 5 mg amlodipine plus 80 mg valsartan or 8 mg candes-artan for at least 2 months. A screening period of up to 2&#x02013; 4 weeks was used to assess eligibility and to eliminate prior medications.  Finally eligible 47 patients (36 males and 11 females, mean age; 64.8 &#x000b1; 12.1 years old) were assigned to replace valsartan or candesartan with 40 mg telmisartan. During the study period, subjects were instructed not to change their lifestyles and to continue taking the same dose of any concomitant drugs. We excluded any patients with secondary hyperten sion, chronic liver disease, severe chronic heart failure, and those who had recent (&#x0003c;6 months) acute coronary syndromes, stroke and any acute infections. Patients whose age was younger than 20 years old, whose BP level was &#x02265; 180/110 mmHg, or whose serum Cr level was &#x02265; 1.5 mg/dL were also excluded. At baseline, 4, 8 and 12 weeks after the replacement, clinic BP level was monitored. Anthropometric and metabolic variables and serum chemistries were also measured at baseline and at 12 weeks after telmisartan treatment as described previously [<xref ref-type="bibr" rid="B28">28</xref>]. Only one male patient on switching from valsartan to telmisartan was dropped out at 8 weeks because of his personal reason. Informed consent was obtained from all the subjects, and the study protocol was approved by the Institutional Ethics Committee of Kurume University School of Medicine.</p></sec><sec sec-type="subsection" id="sec4.2"><title>
					Study design
					</title><p>The medical history was ascertained by a questionnaire. Height and weight were measured, and body mass index (BMI: kilograms per meter squared) was calculated as an index of the presence or absence of obesity. Clinic BP was measured in the sitting position using an upright standard sphygmomanometer after at least 5 min of rest in the morning before taking anti-hypertensive agents. Three measurements were taken 1 min apart, and mean of the last two recordings was used as BP level. Using applanation tonometry (HEM-9000AI (Omron Healthcare, Kyoto, Japan), cBP was deduced noninvasively from the amplitude of the late systolic peak (SBP2) of the radial artery described elsewhere [<xref ref-type="bibr" rid="B29">29</xref>]. The AI was calculated as the ratio of the amplitude of SBP2 to the amplitude of the early systolic peak.</p><p>Blood was drawn from the antecubital vein in the morning after 12-hour fast for determinations of lipids (HDL-C, LDL-C, and TG), FPG, insulin, HbA1c, and Cr. Blood chemistries were mea- sured at a commercially available laboratory (SRL Inc., Hachioji, Japan). The HOMA-IR index was calculated from the values of FPG (mg/dl) and insulin (<italic>&#x003bc;</italic>U/ml) using the following formula [(glucose x insulin)/405]. eGFR was calculated with the modified isotope dilution mass spectrometry (IDMS)-traceable 4-variable Modification of Diet in Renal Disease (MDRD) Study equation for Japanese [<xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec sec-type="subsection" id="sec4.3"><title>
						Statistical methods
					</title><p>Data were expressed as mean &#x000b1; standard deviation (SD). To compare the parameter changes between baseline and after the telmisartan treatment, we used the paired t-test. Statistical significance was defined as p &#x0003c; 0.05. All statistical analyses were performed with the use of the SAS version 9.2 system (SAS Institute Inc., Cary, NC).</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported in part by Grants of Collaboration with Venture Companies Project from the Ministry of Education, Culture, Sports, Science and Technolog y, Japan (S.Y ).</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>HR</given-names></name></person-group><article-title>The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure</article-title><source><italic>American Journal of Hypertension</italic></source><year>2003</year><volume>16</volume><issue>9</issue><fpage>4S</fpage><lpage>6S</lpage><pub-id pub-id-type="pmid">14511895</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Thijs</surname><given-names>L</given-names></name></person-group><article-title>Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003</article-title><source><italic>Journal of Hypertension</italic></source><year>2003</year><volume>21</volume><issue>6</issue><fpage>1055</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">12777939</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbull</surname><given-names>F</given-names></name></person-group><article-title>Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials</article-title><source><italic>The Lancet</italic></source><year>2003</year><volume>362</volume><issue>9395</issue><fpage>1527</fpage><lpage>1535</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higaki</surname><given-names>J</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Katsuya</surname><given-names>T</given-names></name><etal/></person-group><article-title>Deletion allele of angiotensin-con-verting enzyme gene increases risk of essential hyper-tension in Japanese men: the Suita Study</article-title><source><italic>Circulation</italic></source><year>2000</year><volume>101</volume><fpage>2060</fpage><lpage>2065</lpage><pub-id pub-id-type="pmid">10790347</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>SI</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name></person-group><article-title>Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> (PPAR-<italic>&#x003b3;</italic>)-modulating activity for the treatment of cardiometabolic disorders</article-title><source><italic>Current Molecular Medicine</italic></source><year>2007</year><volume>7</volume><issue>5</issue><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">17691961</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamerson</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>MA</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2008</year><volume>359</volume><issue>23</issue><fpage>2417</fpage><lpage>2428</lpage><pub-id pub-id-type="pmid">19052124</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnier</surname><given-names>M</given-names></name><name><surname>Brunner</surname><given-names>HR</given-names></name></person-group><article-title>Angiotensin II receptor antagonists</article-title><source><italic>The Lancet</italic></source><year>2000</year><volume>355</volume><issue>9204</issue><fpage>637</fpage><lpage>645</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>BM</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name><name><surname>De Zeeuw</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2001</year><volume>345</volume><issue>12</issue><fpage>861</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">11565518</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pylypchuk</surname><given-names>GB</given-names></name></person-group><article-title>ACE inhibitor-Versus angiotensin II blocker-induced cough and angioedema</article-title><source><italic>Annals of Pharmacotherapy</italic></source><year>1998</year><volume>32</volume><issue>10</issue><fpage>1060</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">9793599</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDowell</surname><given-names>SE</given-names></name><name><surname>Coleman</surname><given-names>JJ</given-names></name><name><surname>Ferner</surname><given-names>RE</given-names></name></person-group><article-title>Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine</article-title><source><italic>British Medical Journal</italic></source><year>2006</year><volume>332</volume><issue>7551</issue><fpage>1177</fpage><lpage>1180</lpage><pub-id pub-id-type="pmid">16679330</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><etal/></person-group><article-title>2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source><italic>European Heart Journal</italic></source><year>2007</year><volume>28</volume><issue>12</issue><fpage>1462</fpage><lpage>1536</lpage><pub-id pub-id-type="pmid">17562668</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>S</given-names></name><name><surname>Ozawa</surname><given-names>M</given-names></name><name><surname>Tochikubo</surname><given-names>O</given-names></name><name><surname>Umemura</surname><given-names>S</given-names></name></person-group><article-title>Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life</article-title><source><italic>Clinical and Experimental Hypertension</italic></source><year>2009</year><volume>31</volume><issue>8</issue><fpage>680</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">20001460</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>SI</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name></person-group><article-title>Advanced glycation end products, oxidative stress and diabetic nephropathy</article-title><source><italic>Oxidative Medicine and Cellular Longevity</italic></source><year>2010</year><volume>3</volume><issue>2</issue><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">20716934</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elahi</surname><given-names>MM</given-names></name><name><surname>Kong</surname><given-names>YX</given-names></name><name><surname>Matata</surname><given-names>BM</given-names></name></person-group><article-title>Oxidative stress as a mediator of cardiovascular disease</article-title><source><italic>Oxidative Medicine and Cellular Longevity</italic></source><year>2009</year><volume>2</volume><issue>5</issue><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">20716913</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higaki</surname><given-names>J</given-names></name></person-group><article-title>The ideal combination of anti-hypertensive drugs</article-title><source><italic>Hypertension Research</italic></source><year>2009</year><volume>32</volume><issue>12, article 1059</issue></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><etal/></person-group><article-title>The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report</article-title><source><italic>Journal of the American Medical Association</italic></source><year>2003</year><volume>289</volume><issue>19</issue><fpage>2560</fpage><lpage>2572</lpage><pub-id pub-id-type="pmid">12748199</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipp</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>TR</given-names></name><name><surname>Glazer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension</article-title><source><italic>Clinical Therapeutics</italic></source><year>2007</year><volume>29</volume><issue>4</issue><fpage>563</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">17617280</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrysant</surname><given-names>SG</given-names></name><name><surname>Melino</surname><given-names>M</given-names></name><name><surname>Karki</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Heyrman</surname><given-names>R</given-names></name></person-group><article-title>The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study</article-title><source><italic>Clinical Therapeutics</italic></source><year>2008</year><volume>30</volume><issue>4</issue><fpage>587</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">18498909</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Lacy</surname><given-names>PS</given-names></name><name><surname>Thom</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study</article-title><source><italic>Circulation</italic></source><year>2006</year><volume>113</volume><issue>9</issue><fpage>1213</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">16476843</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>I</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association between central systolic blood pressure, white matter lesions in cerebral MRI and carotid atherosclerosis</article-title><source><italic>Hypertension Research</italic></source><year>2009</year><volume>32</volume><issue>10</issue><fpage>869</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">19644503</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakuta</surname><given-names>H</given-names></name><name><surname>Sudoh</surname><given-names>K</given-names></name><name><surname>Sasamata</surname><given-names>M</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name></person-group><article-title>Telmisartan has the strongest binding affinity to angio- tensin II type 1 receptor: comparison with other angio- tensin II type 1 receptor blockers</article-title><source><italic>International Journal of Clinical Pharmacology Research</italic></source><year>2005</year><volume>25</volume><fpage>414</fpage><lpage>416</lpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wienen</surname><given-names>W</given-names></name><name><surname>Entzeroth</surname><given-names>M</given-names></name><name><surname>Van Meel</surname><given-names>JCA</given-names></name><etal/></person-group><article-title>A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist</article-title><source><italic>Cardiovascular Drug Reviews</italic></source><year>2000</year><volume>18</volume><issue>2</issue><fpage>127</fpage><lpage>156</lpage></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><name><surname>Krzesinski</surname><given-names>JM</given-names></name><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Davidai</surname><given-names>G</given-names></name><name><surname>Schumacher</surname><given-names>H</given-names></name></person-group><article-title>Sustained antihypertensive activity of telmisartan compared with valsartan</article-title><source><italic>Blood Pressure Monitoring</italic></source><year>2004</year><volume>9</volume><issue>4</issue><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">15311147</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littlejohn</surname><given-names>T</given-names></name><name><surname>Mroczek</surname><given-names>W</given-names></name><name><surname>Marbury</surname><given-names>T</given-names></name><name><surname>VanderMaelen</surname><given-names>CP</given-names></name><name><surname>Dubiel</surname><given-names>RF</given-names></name></person-group><article-title>A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring</article-title><source><italic>Canadian Journal of Cardiology</italic></source><year>2000</year><volume>16</volume><issue>9</issue><fpage>1123</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">11021956</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><name><surname>Lenis</surname><given-names>J</given-names></name><name><surname>Orchard</surname><given-names>R</given-names></name><etal/></person-group><article-title>A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine</article-title><source><italic>Blood Pressure Monitoring</italic></source><year>1998</year><volume>3</volume><issue>5</issue><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">10212369</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>RM</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>E</given-names></name><name><surname>Lowy</surname><given-names>A</given-names></name><name><surname>Falvey</surname><given-names>H</given-names></name></person-group><article-title>Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach</article-title><source><italic>International Journal of Clinical Practice</italic></source><year>2009</year><volume>63</volume><issue>5</issue><fpage>766</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">19392925</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name><etal/></person-group><article-title>The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009)). Chapter  2: measurement and clinical  evaluation of blood pressure</article-title><source><italic>Hypertension Research</italic></source><year>2009</year><volume>32</volume><fpage>11</fpage><lpage>23</lpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>N</given-names></name><name><surname>Imaizumi</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>M</given-names></name><name><surname>Yamagishi</surname><given-names>SI</given-names></name></person-group><article-title>Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men</article-title><source><italic>Oxidative Medicine and Cellular Longevity</italic></source><year>2010</year><volume>3</volume><issue>4</issue><fpage>262</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">20972372</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>T</given-names></name><name><surname>Kawada</surname><given-names>T</given-names></name><name><surname>Ibuki</surname><given-names>C</given-names></name><name><surname>Kusama</surname><given-names>Y</given-names></name></person-group><article-title>Obesity as an independent influential factor for reduced radial arterial wave reflection in a middle-aged Japanese male population</article-title><source><italic>Hypertension Research</italic></source><year>2009</year><volume>32</volume><issue>5</issue><fpage>387</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">19325562</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>E</given-names></name><name><surname>Horio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Revised equations for estimated GFR from serum creatinine in Japan</article-title><source><italic>American Journal of Kidney Diseases</italic></source><year>2009</year><volume>53</volume><issue>6</issue><fpage>982</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">19339088</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Bp levels in whole patients. Replacement of valsartan or candesartan by telmisartan showed a significant reduction in both mean systolic blood pressure (SBp) and diastolic blood pressure (DBp) at 4, 8 and 12 weeks. Forty-seven patients (36 males and 11 females) with poorly controlled hypertension were assigned to replace 80 mg valsartan or 8 mg candesartan with 40 mg telmisartan. All patients were taking 5 mg amlodipine. (a) SBp and DBp at baseline (0 week) and at 4, 8 and 12 weeks after telmisartan treatment. (B) Mean changes in SBp and DBp from baseline. ** and ***, p &#x0003c; 0.01 and p &#x0003c; 0.001 compared to the values of baseline, respectively.</p></caption><graphic xlink:href="OXIMED3-179038_342.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Bp levels in patients on switching from valsartan to telmisartan. Replacement of valsartan by telmisartan showed a significant reduction in both mean systolic blood pressure (SBp) and diastolic blood pressure (DBp) at 4, 8 and 12 weeks. Twenty-two patients (17 males and 5 females) with poorly controlled hypertension were as- signed to replace 80 mg valsartan by 40 mg telmisartan. All patients were taking 5 mg amlodipine. (a) SBp and DBp at baseline (0 week) and at 4, 8 and 12 weeks after telmisartan treatment. (B) Mean changes in SBp and DBp from baseline. ** and ***, p &#x0003c; 0.01 and p &#x0003c; 0.001 compared to the values of baseline, respectively.</p></caption><graphic xlink:href="OXIMED3-179038_342.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Bp levels in patients on switching from candesartan to telmisartan. Replacement of candesartan by telmisartan showed a re- duction in both mean systolic blood pressure (SBp) and diastolic blood pressure (DBp) at 4, 8 and 12 weeks. Twenty-five patients (19 males and6 females) with poorly controlled hypertension were assigned to replace 8 mg candesartan by 40 mg telmisartan. All patients were taking5 mg amlodipine. (a) SBp and DBp at baseline (0 week) and at 4, 8 and12 weeks after telmisartan treatment. (B) Mean changes in SBp and DBp from baseline. *, p &#x0003c; 0.05 compared to the values of baseline.</p></caption><graphic xlink:href="OXIMED3-179038_342.003"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Clinical variables at baseline and at 12 weeks after telmisartan treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><bold>Clinical variables </bold></th><th align="center" rowspan="1" colspan="1"><bold>Baseline </bold></th><th align="center" rowspan="1" colspan="1"><bold>At 12 weeks</bold></th><th align="center" rowspan="1" colspan="1"><bold>p-value</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1"> 24.8&#x000b1;3.5</td><td align="center" rowspan="1" colspan="1"> 24.7&#x000b1;3.6</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">heart rate (beats/minute)</td><td align="center" rowspan="1" colspan="1">68.4&#x000b1;11.9</td><td align="center" rowspan="1" colspan="1">68.0&#x000b1;11.2</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">SBp (mmhg)</td><td align="center" rowspan="1" colspan="1">143.7&#x000b1;13.6</td><td align="center" rowspan="1" colspan="1">135.4&#x000b1;14.0</td><td align="center" rowspan="1" colspan="1">p &#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DBp (mmhg)</td><td align="center" rowspan="1" colspan="1">82.3&#x000b1;9.4</td><td align="center" rowspan="1" colspan="1">77.5&#x000b1;9.4</td><td align="center" rowspan="1" colspan="1">p &#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">112.6&#x000b1;29.4</td><td align="center" rowspan="1" colspan="1">111.4&#x000b1;27.0</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">159.9&#x000b1;167.9</td><td align="center" rowspan="1" colspan="1">132.0&#x000b1;74.4</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">hDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">  55.1&#x000b1;12.3</td><td align="center" rowspan="1" colspan="1">54.8&#x000b1;11.2</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">111.5&#x000b1;36.5</td><td align="center" rowspan="1" colspan="1">111.7&#x000b1;42.7</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">hba1c (%)</td><td align="center" rowspan="1" colspan="1">6.0&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">6.0&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting insulin (<italic>&#x003bc;</italic>U/mL)</td><td align="center" rowspan="1" colspan="1">9.1&#x000b1;11.8</td><td align="center" rowspan="1" colspan="1">8.5&#x000b1;10.4</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">hOMa-IR</td><td align="center" rowspan="1" colspan="1">2.4&#x000b1;3.0</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;3.3</td><td align="center" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.7&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">0.7&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1"> 0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (ml/min/1.73m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">79.1&#x000b1;17.2</td><td align="center" rowspan="1" colspan="1">79.6&#x000b1;17.1</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (N)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia (N)</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic kidney disease (N)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular disease (N)</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Replacement of valsartan or candesartan by telmisartan showed a significant reduc- tion in both mean systolic blood pressure (SBp) and diastolic blood pressure (DBp) at 12 weeks. BMI; body mass index, LDL-cholesterol; low-density lipoprotein-cholesterol, hDL-cholesterol; high-density lipoprotein-cholesterol, hba1c; glycosyalted hemoglo- bin, hOMa-IR; homeostasis model assessment of insulin resistance, eGFR; estimated glomerular filtration rate, N; number.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Central Bp at baseline and at 12 weeks after telmisartan treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><bold>Clinical variables </bold></th><th align="center" rowspan="1" colspan="1"><bold>Baseline </bold></th><th align="center" rowspan="1" colspan="1"><bold>At 12 weeks</bold></th><th align="center" rowspan="1" colspan="1"><bold>p-value</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients (N)</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1"> -</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years old)</td><td align="center" rowspan="1" colspan="1">55.1&#x000b1;8.7</td><td align="center" rowspan="1" colspan="1"> -</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Male/female (N)</td><td align="center" rowspan="1" colspan="1">7/1</td><td align="center" rowspan="1" colspan="1">7/1</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">24.7&#x000b1;3.6</td><td align="center" rowspan="1" colspan="1">24.9&#x000b1;3.7</td><td align="center" rowspan="1" colspan="1"> 0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beats/minutes)</td><td align="center" rowspan="1" colspan="1"> 71.3&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1"> 74.3&#x000b1;7.1</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">SBp2 (mmhg)</td><td align="center" rowspan="1" colspan="1">129.3&#x000b1;7.7</td><td align="center" rowspan="1" colspan="1">118.4&#x000b1;9.4</td><td align="center" rowspan="1" colspan="1">p &#x0003c; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Central Bp (mmhg)</td><td align="center" rowspan="1" colspan="1">144.9&#x000b1;8.2</td><td align="center" rowspan="1" colspan="1">133.1&#x000b1;10.1</td><td align="center" rowspan="1" colspan="1">p &#x0003c; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">AI (%)</td><td align="center" rowspan="1" colspan="1"> 71.8&#x000b1;16.5</td><td align="center" rowspan="1" colspan="1"> 72.9&#x000b1;20.0</td><td align="center" rowspan="1" colspan="1">   0.82</td></tr></tbody></table><table-wrap-foot><fn><p>Replacement of valsartan by telmisartan showed a significant reduction in centralblood pressure (central Bp) at 12 weeks. BMI; body mass index, SBp2; late systolic peak of blood pressure, Bp; blood pressure, AI; augmentation index, N; number.</p></fn></table-wrap-foot></table-wrap></floats-group></article>